Trial · NCT00361595
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
NCT00361595, Not applicable, Completed, The Cleveland Clinic; results first posted 2011-01-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women. Trials, record NCT00361595. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00361595
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
- NCT number
- NCT00361595
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 35 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Osteoporosis
- Interventions
- zoledronic acid
- First posted
- 2006-08-08
- Last updated
- 2017-04-21
- Results first posted
- 2011-01-14
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry) | Baseline and 12 months | |
| Secondary | Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months | 6 months and 12 months | Change in bone density (grams/cm\^2) at the total hip at 6 and 12 months. 12 month reported based on usual interval for bone density follow-up in clinical practice. |
| Secondary | Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12) | 12 months | Change in serum c-telopeptide type 1 collagen (CTX) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect. |
| Secondary | Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12) | 12 months | Change in serum n-propeptide type 1 collagen (P1NP) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry) | Baseline and 12 months | grams/cm^2 | MEAN | |
| SECONDARY | Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months | 6 months and 12 months | grams/cm^2 | MEAN | |
| SECONDARY | Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12) | 12 months | ng/ml | MEAN | |
| SECONDARY | Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12) | 12 months | mcg/ml | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry) | Open Label | 2.2 | Standard Deviation .036 | grams/cm^2 | |
| Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months | Open Label | 2.4 | Standard Deviation .031 | grams/cm^2 | |
| Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12) | Open Label | -49.1 | Standard Deviation 37.6 | ng/ml | |
| Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12) | Open Label | -66.2 | Standard Deviation 29.1 | mcg/ml |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Open Label | 35 | |
| Overall Study | COMPLETED | Open Label | 35 | |
| Overall Study | NOT COMPLETED | Open Label | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Transient increase in serum creatinine | Blood and lymphatic system disorders | Open Label | 2 | 35 | 2 |
| other | Flu-like symptoms | General disorders | Open Label | 6 | 35 | 6 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Open Label | ||
| Total, other adverse events | Open Label | 8 | 35 |
| Total, serious adverse events | Open Label | 0 | 35 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00361595
GET https://conductscience.org/api/trials/v1/NCT00361595/registered